ArticleSurgical case reports2026
A Case of Unresectable Ampulla of Vater Carcinoma Successfully Treated with Conversion Surgery Following Sequential Systemic Chemotherapy Including Durvalumab.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe criteria for indications and postoperative treatment strategies for conversion surgery in patients with unresectable ampulla of Vater carcinoma with distant metastasis have not been clarified. We present an unusual case of a patient with initially unresectable ampulla of Vater carcinoma with multiple liver metastases who underwent conversion surgery after treatment with durvalumab and gemcitabine plus cisplatin. CASE PRESENTATION: A 69-year-old male was found to have ampulla of Vater carcinoma with multiple liver metastases. A diagnosis of unresectable ampulla of Vater carcinoma was made, and the treatment plan was chemotherapy. After 12 cycles of gemcitabine, cisplatin, and S-1, the tumor did not shrink. Six cycles of gemcitabine, cisplatin, and durvalumab were then administered. The metastases were obscured on imaging; however, micrometastases were observed on the liver surface by staging laparoscopy. Six additional cycles of gemcitabine, cisplatin, and durvalumab were administered, and the disappearance of metastases was confirmed by staging laparoscopy. The patient then underwent conversion surgery with subtotal gastric-preserving pancreaticoduodenectomy. Pathology revealed a complete response, and radical resection was successfully performed. Immunostaining of tissue collected during endoscopic ultrasound-guided acquisition revealed less than 1% expression of programmed death ligand-1.
conclusionsSequential systemic chemotherapy including durvalumab is suggested as a useful future treatment option and may contribute to conversion surgery for unresectable ampulla of Vater carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.